Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.443
Neutral
RSI(14)
49.096
Neutral
STOCH(KDJ)(9,3,3)
19.539
Sell
ATR(14)
1.227
Low Volatility
CCI(14)
-127.070
Sell
Williams %R
92.926
Oversold
TRIX(12,20)
0.572
Sell
StochRSI(14)
0.000
Oversold
Search
Avalo Therapeutics Inc
AVTXAdd to Watchlist
17.770USD
-0.380-2.09%
Close 07-23 16:00（ET）Quotes delayed by 15 min
437.81MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
-2.09%
5 Days
-0.62%
1 Month
-0.34%
6 Months
+12.83%
Year to Date
-2.15%
1 Year
+166.42%
Key Figures
17.840Open
18.280High
527.83KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
2.14%Turnover Ratio
18.150Prev. Close
17.750Low
7.45MTurnover
LossP/E Static
6.41P/B
0.00%Div Yield TTM
-71.09%ROA
24.27052wk High
0.53Volume Ratio
-35.13MNet Profit
24.64MShares
-5.5639EPS TTM
0.84Beta
-88.76%ROE
3.58052wk Low
2.92%Amplitude
100.00%Gross Margin
437.81MMarket Cap
-0.01Reward/Risk
5.02%Risk Rate
TradingKey Stock Score of Avalo Therapeutics Inc
Currency: USD Updated: 2026-07-23Key Insights
Avalo Therapeutics Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 132 out of 386 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 45.50.In the medium term, the stock price is expected to trend up.The company has shown average stock market performance over the past month, with weak fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Avalo Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Avalo Therapeutics Inc Highlights
StrengthsRisks
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases. IL-1β is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology. AVTX-009 is in the Phase II LOTUS trial for hidradenitis suppurativa (HS).
Growing
The company is in a growing phase, with the latest annual income totaling USD 59.00K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 59.00K.
Undervalued
The company’s latest PE is -3.19, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 24.87M shares, increasing 21.84% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 866.37K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 2.38.
Analyst Rating
Based on
15
analysts
Strong Buy
Current Rating
45.500
Target Price
+141.76%
Upside Space
Avalo Therapeutics Inc News
More news coming soon, stay tuned...
Indicators
Moving Average
Indicators
Value
Direction
MA5
18.462
Sell
MA10
18.528
Sell
MA20
18.687
Sell
MA50
16.906
Buy
MA100
16.251
Buy
MA200
16.372
Buy
Avalo Therapeutics Inc Info
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases. IL-1β is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology. AVTX-009 is in the Phase II LOTUS trial for hidradenitis suppurativa (HS).
Ticker SymbolAVTX
CompanyAvalo Therapeutics Inc
CEONeil (Garry A)
Websitehttps://www.avalotx.com/
Related Instruments
+1.95%
+1.46%
-0.85%
+1.43%
+2.37%
+2.01%
+1.49%
+0.38%
0.00%
+0.71%
+1.27%
+0.15%
-0.94%
-0.03%
+1.31%
0.00%
+0.11%
+8.61%
-0.21%
+2.45%Popular Instruments
FAQs
What is the current price of Avalo Therapeutics Inc (AVTX)?
The current price of Avalo Therapeutics Inc (AVTX) is 17.77.
What is the symbol of Avalo Therapeutics Inc?
The ticker symbol of Avalo Therapeutics Inc is AVTX.
What is the 52-week high of Avalo Therapeutics Inc?
The 52-week high of Avalo Therapeutics Inc is 24.27.
What is the 52-week low of Avalo Therapeutics Inc?
The 52-week low of Avalo Therapeutics Inc is 3.58.
What is the market capitalization of Avalo Therapeutics Inc?
The market capitalization of Avalo Therapeutics Inc is 437.81M.
Is Avalo Therapeutics Inc (AVTX) currently rated as Buy, Hold, or Sell?
According to analysts, Avalo Therapeutics Inc (AVTX) has an overall rating of STRONG BUY, with a price target of 45.50.
What is the Earnings Per Share (EPS TTM) of Avalo Therapeutics Inc (AVTX)?
The Earnings Per Share (EPS TTM) of Avalo Therapeutics Inc (AVTX) is -5.84.